Ocean Biomedical

Ocean Biomedical is a biopharmaceutical company that operates a unique business model focused on commercializing high-potential scientific discoveries from top-tier research universities. The company's pipeline is primarily built on licensed technology from Brown University and Rhode Island Hospital, targeting significant unmet needs in oncology, fibrosis, and infectious diseases. Key programs include monoclonal antibodies targeting CHI3L1 for the treatment of non-small cell lung cancer and glioblastoma, as well as small molecule inhibitors of CHIT1 for idiopathic pulmonary fibrosis. Additionally, Ocean Biomedical is developing a portfolio of malaria vaccine candidates based on novel parasite antigens. The company aims to bridge the "valley of death" in drug development by providing the capital and expertise necessary to move academic research into clinical trials.